Prof Antoine Italiano speaks to ecancer about a phase 2 REGOMUNE trial.

In this trial, researchers investigated the effectiveness of combining avelumab and regorafenib for treating solid tumours with tertiary lymphoid structures.

This was the first clinical trial that employed mature tertiary lymphoid structures (mTLS) as a biomarker for patient selection for treatment with an immune checkpoint inhibitor-based regimen.

The study results showed that even patients who are typically resistant to immunotherapy experienced long-lasting responses.

This confirms the predictive value of mTLS.